Adult Stem Cells for Regenerative Therapy – PubMed

Cell therapy has been identified as an effective method to regenerate damaged tissue. Adult stem cells, also known as somatic stem cells or resident stem cells, are a rare population of undifferentiated cells, located within a differentiated organ, in a specialized structure, called a niche, which maintains the microenvironments that regulate the growth and development of adult stem cells. The adult stem cells are self-renewing, clonogenic, and multipotent in nature, and their main role is to maintain the tissue homeostasis. They can be activated to proliferate and differentiate into the required type of cells, upon the loss of cells or injury to the tissue. Adult stem cells have been identified in many tissues including blood, intestine, skin, muscle, brain, and heart. Extensive preclinical and clinical studies have demonstrated the structural and functional regeneration capabilities of these adult stem cells, such as bone marrow-derived mononuclear cells, hematopoietic stem cells, mesenchymal stromal/stem cells, resident adult stem cells, induced pluripotent stem cells, and umbilical cord stem cells. In this review, we focus on the human therapies, utilizing adult stem cells for their regenerative capabilities in the treatment of cardiac, brain, pancreatic, and eye disorders.

Keywords: Blood disorders; Cardiospheres; Diabetes mellitus; Myoblasts; Neurogenesis; Regenerative therapy; Stem cells; Stroke.

Read more:
Adult Stem Cells for Regenerative Therapy - PubMed

About Adult Stem Cell Therapy – University of Kansas Medical Center

Adult Stem Cell Therapy 101

The initial concept of regenerative medicine dates all the way back to 330 BC, when Aristotle observed that a lizard could grow back the lost tip of its tail.

Slowly over time, humans have grown to understand regenerative medicine, and how it may change the way we treat diseases. It's been only relatively recently that adult (non-embryonic) stem cell therapy, a type of regenerative medicine, has gathered fast momentum.

Adult (non-embryonic) stem cells are unspecialized or undifferentiated cells, which means they have yet to develop into a specific cell type. Found in most adult tissues, adult stem cells have two primary properties:

Simply put, adult stem cells have the potential to grow into any of the body's more than 200 cell types.

Adult stem cells have been found in most parts of the body, including brain, bone marrow, blood vessels, skin, teeth and heart. There are typically a small number of stem cells in each tissue. Due to their small number and rate of division (growth), it is difficult to grow adult stem cells in large numbers.

Scientists at the Midwest Stem Cell Therapy Center are working to understand how to grow large amounts of adult stem cells in cell culture. These scientists are also working with more "primitive" stem cells, isolated from the umbilical cord after normal births.

Stem cell transplants, also referred to as bone marrow transplants, have been done since the late 1960s and are well-established treatments for blood cancers and bone marrow failure conditions. Umbilical cord blood also has stem cells that can be used for transplantation for these diseases.

Stem cell transplants for other diseases that use bone marrow, umbilical cord cells or other sources of stem cells are still experimental and need to viewed as such.

The practice of stem cell therapy is not new: One of the oldest forms of it is the bone marrow transplant, which has been actively practiced since the late 1960s. Since then, scientists haven't slowed down with the advancement of adult stem cell therapy.

Every day, scientists worldwide are researching new ways we can harness stem cells to develop effective new treatments for a host of diseases. In the case of a patient suffering with a blood cancer such as leukemia, a bone marrow transplant will replace their unhealthy blood cells with healthy ones.

This same concept inserting healthy cells so they may multiply and form new tissue or repair diseased tissue can be applied to other forms of stem cell therapy.

Stem cell research continues to advance as scientists learn how an organism develops from a single cell and how healthy cells replace damaged cells.

For example, the Midwest Stem Cell Therapy Center is collaborating to investigate the potential of a select group of umbilical cord stem cells in the treatment of Amyotrophic Lateral Sclerosis (ALS, or Lou Gerhig's disease).

Developing a stem cell treatment that has been shown to be both safe and efficacious is not as simple as removing stem cells from one part of the body and putting it in another.

Working with appropriate regulatory agencies, the Midwest Stem Cell therapy Center is conducting R&D activities that will permit the Center to conduct human clinical trials on a variety of diseases over the next several years.

Similar to the development of a new drug, this process when completed, will assure patients in both clinical trials and eventually patients using the approved product, that the product is safe for use in humans and the stem cells being administered are effective in treating the injury or disease they are being used for.

Read more:
About Adult Stem Cell Therapy - University of Kansas Medical Center

for Human Stem Cell Research – ahrq.gov

NICHD ADMINISTRATIVE SUPPLEMENTS FOR HUMAN EMBRYONIC STEM CELL RESEARCH RELEASE DATE: January 24, 2003 NOTICE: NOT-HD-03-005Update: July 7, 2009 This Notice is superseded by NIH-OD-09-116 NIH Guidelinesfor Human Stem Cell ResearchNational Institute of Child Health and Human Development (NICHD) (http://www.nichd.nih.gov/)The National Institute of Child Health and Human Development (NICHD) announces the availability of administrative supplements to NICHD grantees to conduct research using human embryonic stem cell lines (ESCs) in accordance with the NIH-wide announcement and guidancethat can be found athttps://grants.nih.gov/grants/guide/notice-files/NOT-OD-02-006.html. The human ESCs to be used must be listed on the NIH Human Embryonic Stem Cell Registry (http://escr.nih.gov/). Principal Investigators of NICHD-funded R01, R37, and P01 grants may request an administrative supplement not to exceed $75,000 direct costs (three modules) per year for two years. There must be at least two years of funding remaining on the parent grant at the time the supplement is awarded. It is intended that awards will be initiated in FY 2003 and FY 2004. Requests must be submitted not later than July 1, 2003 for FY 2003 funding or July 1, 2004 for FY 2004 funding.The work proposed must be within the scope of the parent R01, R37 or P01 grant. For example, investigators may apply concepts and technologies being used on any nonhuman adult or embryonic cells in the funded project to the study of human ESCs. The proposed research can utilize the full range of cell biological, genetic or molecular approaches. The request for an administrative supplement must include a careful description of the work proposed, an explanation of the relationship to the parent grant, and a justification for the study. The NICHD intends to commit up to $500,000 direct costs per year for this initiative in FY 2003 and FY 2004. This is a one-time announcement. However, the NICHD may re-release the announcement depending upon the needs of the NICHD scientific community and the availability of funds. Requests will be reviewed by NICHD staff. Awards will be dependent upon the receipt of qualified requests and the availability of funds. Grantees may request funds for small items of equipment, supplies, purchase of human ESCs, and personnel to work with human ESCs. Funds may also be requested to support travel and other costs needed to acquire necessary expertise in the handling of human ESCs. Investigators must independently contact the human ESC providers listed on the NIH Registry and make arrangements to obtain the cell lines, including any required material transfer agreements (MTA). Applicants must indicate which human ESC lines will be used. A letter indicating that the provider has agreed to supply the human ESC line must be furnished either with the application (see below) or just prior to the award. The investigators also should either demonstrate prior ability to work with human ESCs or outline plans for obtaining training to culture human ESCs. The human ESC providers, other laboratories with ESC experience, or laboratory training courses on ESC methods are potential means of obtaining this training. Other means for acquiring human ESC expertise may be proposed. Application ProceduresIn order to apply for an administrative supplement, it is advisable to first discuss your request with the NICHD Program Director who manages your grant or with Dr. Tasca at the address below. After this discussion, send an original letter, co-signed by the business official of the grantee institution, to your Program Director, with one copy to Dr. Tasca (below) and one copy to Ms. Hancock (below). The letter (two page limit) should include: 1) an abstract of the proposed supplemental activity and how it is related to the parent grant; 2) a description of how the requested supplement will provide the resources and expertise necessary to design and perform the experiments using human ESCs; 3) the NIH code for the selected human ESC line(s); 4) details of the budget items requested and funding period; and 5) current contact information for the Principal Investigator, including postal and email addresses. Although these descriptions should be as concise as possible, sufficient detail must be provided to allow the NICHD to determine if the request qualifies as an administrative supplement. INQUIRIESDirect inquiries regarding program and scientific issues to: Dr. Richard J. Tasca Reproductive Sciences Branch Center for Population Research National Institute of Child Health and Human Development 6100 Executive Boulevard, Room 8B01, MSC 7510 Bethesda, MD 20892-7510 Telephone: (301) 435-6973 FAX: (301) 480-2389 Email: rt34g@nih.gov Direct questions about financial or grants management issues to: Kathy Hancock Grants Management Branch National Institute of Child Health and Human Development 6100 Executive Boulevard, Room 8A17, MSC 7510 Bethesda, MD 20892-7510 Telephone: (301) 496-5482 FAX: (301) 480-4782 Email: kh47d@nih.gov

Weekly TOC for this Announcement NIH Funding Opportunities and Notices

Read this article:
for Human Stem Cell Research - ahrq.gov

What are the differences between Stem Cells and Somatic Cells?

Any cell type in a multicellular organism, except germline cells, is called a somatic cell. In contrast, stem cells are unspecialized cells with self-renewal capacity that can divide limitlessly to produce new stem cells, as well can differentiate to different cell types in the body.

Somatic cells are diploid cells, which contain two pairs of chromosomes, one received from each parent. Any cell other than germ cells (sperm and egg), gametocytes (cells that divide to form germ cells), and undifferentiated stem cells are known as somatic cells.

Unlike germ cells, somatic cells are not capable of producing offspring; instead, they form all the internal organs and tissues and contribute significantly to their functionalities.

Meiosis. Image Credit: Ody_Stocker/Shutterstock.com

Stem cells are unspecialized cells with self-renewal capacity. They can divide through mitosis limitlessly to replenish other cell types of multicellular organisms throughout their life.

After stem cell division, each newly produced cell can either remain as a stem cell or differentiate to form any other cell type with more defined functions, such as muscle cell, blood cell, or neural cell.

Under special circumstances, differentiation of stem cells can also be induced to generate tissue- or organ-specific cell types with special functions. There are mainly two types of stem cells: embryonic stem cells, which are derived from embryos, and somatic or adult stem cells, which are undifferentiated cells residing in a tissue or organ along with other differentiated cells (somatic cells).

Image Credit: Designua/Shutterstock.com

The major difference between embryonic and somatic stem cells is that embryonic stem cells have the potential to differentiate into all cell types of the body, as they are pluripotent stem cells (cells that are able to differentiate into three primary germ cell layers of the early embryo and, thus, into any cell type of the body); whereas, it is believed that somatic stem cells can differentiate only into different cell types present in the tissue of their origin.

Another type of genetically modified stem cell is induced pluripotent stem cell (iPSC). These cells are somatic stem cells that are genetically reprogramed to become like embryonic stem cells by inducing expressions of specific genes and other components necessary for maintaining embryonic stem cell properties.

Adult stem cells reside along with somatic cells in many tissues and organs, including peripheral blood, blood vessels, bone marrow, skeletal muscle, teeth, skin, gut, liver, ovary, testis, brain, and heart.

They are present in a small number and located in a specific area of each tissue called stem cell niche. Unlike somatic cells, stem cells can be in an inactive, non-dividing state for a long time until they are activated by certain internal or external signals, such as tissue injury or diseased conditions.

Adult stem cells can undergo normal differentiation pathways to give rise to specialized cells of the tissue wherein they are located. Some examples of stem cell differentiation into specialized somatic cells are as follows:

Hematopoietic stem cells differentiate into all types of blood cells, including red blood cells (RBC), B lymphocytes, T lymphocytes, neutrophils, basophiles, eosinophils, monocytes, natural killer cells, and macrophages.

Mesenchymal stem cells also known as bone marrow stromal stem cells, differentiate into different cell types, including bone cells, cartilage cells, fat cells, and stromal cells, that regulate blood production.

Neural stem cells are present in the brain and can differentiate into three major brain cell types namely neurons (nerve cells), astrocytes, and oligodendrocytes.

Epithelial stem cells are present in the epithelial lining of the gastrointestinal tract and can differentiate into different cell types, including absorptive cells, goblet cells, and enteroendocrine cells.

Skin stem cells are of two types: epidermal stem cells that are found in the basal layer of the epidermis and can differentiate into keratinocytes; and follicular stem cells that are found at the base of hair follicles and can differentiate into both follicular cells and keratinocytes.

Besides normal differentiation, adult stem cells sometimes undergo transdifferentiation, a process by which stem cells from a particular tissue differentiate into specialized cell types of another tissue. For instance, stem cells from the brain give rise to blood cells.

Despite many functional differences between stem cells and somatic cells, the ability of stem cells to differentiate into specialized cell types of the body has uncovered a potential way toward cell-based therapies, where stem cells can be used as a renewable source for replacing damaged somatic cells to treat many detrimental disorders, including heart diseases, stroke, spinal cord injury, macular degeneration, diabetes, rheumatoid arthritis, etc.

Go here to read the rest:
What are the differences between Stem Cells and Somatic Cells?

Stem Cell Basics | STEM Cell Information – National Institutes of Health

I. Introduction: What are stem cells, and why are they important?

Stem cells have the remarkable potential to renew themselves. They can develop into many different cell types in the body during early life and growth. Researchers study many different types of stem cells. There are several main categories: the pluripotent stem cells (embryonic stem cells and induced pluripotent stem cells) and nonembryonic or somatic stem cells (commonly called adult stem cells). Pluripotent stem cells have the ability to differentiate into all of the cells of the adult body. Adult stem cells are found in a tissue or organ and can differentiate to yield the specialized cell types of that tissue or organ.

Pluripotent stem cells

Early mammalian embryos at the blastocyst stage contain two types of cells cells of the inner cell mass, and cells of the trophectoderm. The trophectodermal cells contribute to the placenta. The inner cell mass will ultimately develop into the specialized cell types, tissues, and organs of the entire body of the organism. Previous work with mouse embryos led to the development of a method in 1998 to derive stem cells from the inner cell mass of preimplantation human embryos and to grow human embryonic stem cells (hESCs) in the laboratory. In 2006, researchers identified conditions that would allow some mature human adult cells to be reprogrammed into an embryonic stem cell-like state. Those reprogramed stem cells are called induced pluripotent stem cells (iPSCs).

Adult stem cells

Throughout the life of the organism, populations of adult stem cells serve as an internal repair system that generates replacements for cells that are lost through normal wear and tear, injury, or disease. Adult stem cells have been identified in many organs and tissues and are generally associated with specific anatomical locations. These stem cells may remain quiescent (non-dividing) for long periods of time until they are activated by a normal need for more cells to maintain and repair tissues.

Stem cells have unique abilities to self-renew and to recreate functional tissues.

Stem cells have the ability to self-renew.

Unlike muscle cells, blood cells, or nerve cellswhich do not normally replicate stem cells may replicate many times. When a stem cell divides, the resulting two daughter cells may be: 1) both stem cells, 2) a stem cell and a more differentiated cell, or 3) both more differentiated cells. What controls the balance between these types of divisions to maintain stem cells at an appropriate level within a given tissue is not yet well known.

Discovering the mechanism behind self-renewal may make it possible to understand how cell fate (stem vs. non-stem) is regulated during normal embryonic development and post-natally, or misregulated as during aging, or even in the development of cancer. Such information may also enable scientists to grow stem cells more efficiently in the laboratory. The specific factors and conditions that allow pluripotent stem cells to remain undifferentiated are of great interest to scientists. It has taken many years of trial and error to learn to derive and maintain pluripotent stem cells in the laboratory without the cells spontaneously differentiating into specific cell types.

Stem cells have the ability to recreate functional tissues.

Pluripotent stem cells are undifferentiated; they do not have any tissue-specific characteristics (such as morphology or gene expression pattern) that allow them to perform specialized functions. Yet they can give rise to all of the differentiated cells in the body, such as heart muscle cells, blood cells, and nerve cells. On the other hand, adult stem cells differentiate to yield the specialized cell types of the tissue or organ in which they reside, and may have defining morphological features and patterns of gene expression reflective of that tissue.

Different types of stems cells have varying degrees of potency; that is, the number of different cell types that they can form. While differentiating, the cell usually goes through several stages, becoming more specialized at each step. Scientists are beginning to understand the signals that trigger each step of the differentiation process. Signals for cell differentiation include factors secreted by other cells, physical contact with neighboring cells, and certain molecules in the microenvironment.

How are stem cells grown in the laboratory?

Growing cells in the laboratory is known as cell culture. Stem cells can proliferate in laboratory environments in a culture dish that contains a nutrient broth known as culture medium (which is optimized for growing different types of stem cells). Most stem cells attach, divide, and spread over the surface of the dish.

The culture dish becomes crowded as the cells divide, so they need to be re-plated in the process of subculturing, which is repeated periodically many times over many months. Each cycle of subculturing is referred to as a passage. The original cells can yield millions of stem cells. At any stage in the process, batches of cells can be frozen and shipped to other laboratories for further culture and experimentation.

How do you reprogram regular cells to make iPSCs?

Differentiated cells, such as skin cells, can be reprogrammed back into a pluripotent state. Reprogramming is achieved over several weeks by forced expression of genes that are known to be master regulators of pluripotency. At the end of this process, these master regulators will remodel the expression of an entire network of genes. Features of differentiated cells will be replaced by those associated with the pluripotent state, essentially reversing the developmental process.

How are stem cells stimulated to differentiate?

As long as the pluripotent stem cells are grown in culture under appropriate conditions, they can remain undifferentiated. To generate cultures of specific types of differentiated cells, scientists may change the chemical composition of the culture medium, alter the surface of the culture dish, or modify the cells by forcing the expression of specific genes. Through years of experimentation, scientists have established some basic protocols, or recipes, for the differentiation of pluripotent stem cells into some specific cell types (see Figure 1 below).

What laboratory tests are used to identify stem cells?

At various points during the process of generating stem cell lines, scientists test the cells to see whether they exhibit the fundamental properties that make them stem cells. These tests may include:

Given their unique regenerative abilities, there are many ways in which human stem cells are being used in biomedical research and therapeutics development.

Understanding the biology of disease and testing drugs

Scientists can use stem cells to learn about human biology and for the development of therapeutics. A better understanding of the genetic and molecular signals that regulate cell division, specialization, and differentiation in stem cells can yield information about how diseases arise and suggest new strategies for therapy. Scientists can use iPSCs made from a patient and differentiate those iPSCs to create organoids (small models of organs) or tissue chips for studying diseased cells and testing drugs, with personalized results.

Cell-based therapies

An important potential application is the generation of cells and tissues for cell-based therapies, also called tissue engineering. The current need for transplantable tissues and organs far outweighs the available supply. Stem cells offer the possibility of a renewable source. There is typically a very small number of adult stem cells in each tissue, and once removed from the body, their capacity to divide is limited, making generation of large quantities of adult stem cells for therapies difficult. In contrast, pluripotent stem cells are less limited by starting material and renewal potential.

To realize the promise of stem cell therapies in diseases, scientists must be able to manipulate stem cells so that they possess the necessary characteristics for successful differentiation, transplantation, and engraftment. Scientists must also develop procedures for the administration of stem cell populations, along with the induction of vascularization (supplying blood vessels), for the regeneration and repair of three-dimensional solid tissues.

To be useful for transplant purposes, stem cells must be reproducibly made to:

While stem cells offer exciting promise for future therapies, significant technical hurdles remain that will likely only be overcome through years of intensive research.

Note: Currently, the only stem cell-based products that are approved for use by the U.S. Food and Drug Administration (FDA) for use in the United States consist of blood-forming stem cells (hematopoietic progenitor cells) derived from cord blood. These products are approved for limited use in patients with disorders that affect the body system that is involved in the production of blood (called the hematopoietic system). TheseFDA-approved stem cell products are listed on the FDA website. Bone marrow also is used for these treatments but is generally not regulated by the FDA for this use. The FDA recommends that people considering stem cell treatments make sure that the treatment is either FDA-approved or being studied under an Investigational New Drug Application (IND), which is a clinical investigation plan submitted and allowed to proceed by the FDA.

NIH conducts and funds basic, translational, and clinical research with a range of different types of stem cells. NIH-supported research with human pluripotent stem cells is conducted under the terms of theNIH Guidelines for Human Stem Cell Research. NIH awards are listed in various categories of stem cell research through theNIH Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC). NIH also supports a major adult stem cell and iPSC research initiative through theRegenerative Medicine Innovation Project.

Go here to read the rest:
Stem Cell Basics | STEM Cell Information - National Institutes of Health

Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022: Development of iPSC-Derived Disease Models Driving Growth – ResearchAndMarkets.com -…

  1. Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022: Development of iPSC-Derived Disease Models Driving Growth - ResearchAndMarkets.com  Business Wire
  2. Induced Pluripotent Stem Cells Production Market by Product Type (Hepatocytes, Fibroblasts, Keratinocytes, Amniotic Cells, Others), Application (Academic Research, Drug Development, Toxicity Screening, Regenerative Medicine), and Geography Global T  Skegness Siren
  3. Global Allogeneic Stem Cell Therapy Market is expected to grow at a CAGR of 9.85% by 2030  Digital Journal
  4. Stem Cell Therapy Global Market Size, Share, Trends Analysis, By Product, By Application, By Technology, By Th  openPR
  5. View Full Coverage on Google News

See original here:
Induced Pluripotent Stem Cell (iPSC) Global Market Report 2022: Development of iPSC-Derived Disease Models Driving Growth - ResearchAndMarkets.com -...